Galderma is launching “Scratch Resistance,” its new broadcast advertisement and first Direct-to-Consumer (DTC) multichannel campaign for nemolizumab-ilto (Nemluvio).
The campaign spotlights the burden of atopic dermatitis (AD) beyond the itch and aims to empower patients to take control of their disease with the interleukin-31 (IL-31) blocker.
The unrelenting itch of AD can make patients resourceful, leading them to scratch with just about anything. Galderma’s “Scratch Resistance” campaign is designed to validate this experience by highlighting different objects people with AD use to scratch their itch and show them that with Nemluvio, you can get over your eczema itch and whatever you use to scratch it.
“Scratch Resistance” will live across broadcast TV channels and will also be featured on consumer-facing platforms across Facebook, Instagram, digital banner ads, and more.
Watch Now:
“Unrelenting itch can have a significant emotional burden, with patients experiencing anxiety, sleep disturbance, frustration, and in severe cases, depression,” says Debra Hagan, Vice President and General Manager, and Head of U.S Therapeutic Dermatology at Galderma, in a news release. “With the launch of ‘Scratch Resistance,’ we hope to bridge the gap between the physical and emotional symptoms of atopic dermatitis and help patients get back to feeling like themselves faster with NEMLUVIO. This campaign underscores our commitment to innovation in dermatology and our dedication to improving the quality of life for those living with atopic dermatitis.”
About Nemolizumab
An interleukin-31 (IL-31) blocker, nemolizumab has been approved by the European Commission for both moderate-to-severe atopic dermatitis and moderate-to-severe prurigo nodularis in the European Union (EU).18 It is now approved in the EU for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.18 The U.S. FDA has also approved nemolizumab for the treatment of adults with prurigo nodularis and patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. Nemolizumab is also under review for the treatment of both diseases by several additional regulatory authorities around the world. Further submissions to regulatory authorities in additional countries are ongoing.
